- Home
- JTAI vs RDHL Comparison
JTAI vs RDHL Comparison
Compare JTAI & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JTAI | RDHL |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | Israel |
| Employees | 8 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.0M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | JTAI | RDHL |
|---|---|---|
| Price | $7.69 | $1.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $80.00 | N/A |
| AVG Volume (30 Days) | ★ 11.4M | 24.1K |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | $0.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $0.71 |
| 52 Week High | $10.41 | $3.31 |
Technical Indicators
Market Signals| Indicator | JTAI | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 83.67 | 69.71 |
| Support Level | $0.61 | $0.79 |
| Resistance Level | $10.41 | $1.07 |
| Average True Range (ATR) | 1.23 | 0.06 |
| MACD | 0.27 | 0.02 |
| Stochastic Oscillator | 74.46 | 82.13 |
Price Performance
Historical ComparisonAbout JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.